TrialPath
Recruiting

A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis

NCT07406035 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Randomized, Placebo- and Active Drug-Controlled, Double-Blind, Multicenter, Parallel-Group Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
About this study
This study is a marketing-oriented clinical trial of TQH3906 Capsules. A total of 156 participants are planned to be enrolled, aiming to evaluate the dose-effect relationship of TQH3906 versus placebo in the treatment of active Psoriatic Arthritis (PsA) at Week 12, with the proportion of participants achieving an American College of Rheumatology 20% (ACR20) Improvement Criteria (ACR20) response at Week 12 as the primary endpoint.
Eligibility criteria
Inclusion Criteria: * Sign a written Informed Consent Form, which must meet the following requirements * Be willing to participate in the study and able to sign the informed consent form; * Be willing and able to complete all study-specific procedures and visits; * PsA trial participant disease characteristics * Aged 18 to 70 years(inclusive); * ii.diagnosed with PsA for at least 3 months prior to screening, and meeting the Classification Criteria for Psoriatic Arthritis (CASPAR) at screening; * Active arthritis at screening and at baseline (Day 1); * Has failed or was intolerant to at least one prior therapy; * If receiving a conventional synthetic Disease-Modifying Antirheumatic Drug (csDMARD), trial participants must be on only one DMARD, which must have been administered for at least 3 months prior to screening, with a stable dose for at least 28 days prior to the first dose; * If using NSAIDs, the dose must have been stable for at least 14 days before the first dose; * If using oral corticosteroids, the dose must have been stable for at least 14 days before the first dose; * Topical treatments for plaque psoriasis must have remained stable for at least 14 days before the first dose; * Female participants of child-bearing potential shall agree to use effective contraception during the study and for 30 days following the last dose, and pregnancy tests at the screening and baseline visits shall be negative; male participants shall agree to use effective contraception during the study and for 30 days following the last dose. Exclusion Criteria: * Presence of conditions other than PsA: * Presence of non-plaque psoriasis (i.e., guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis) at screening or first dose; * Presence of any other autoimmune disease, such as rheumatoid arthritis, systemic lupus erythematosus, etc.; * Presence of active (i.e., currently symptomatic) fibromyalgia; * Other Medical Conditions and Medical History: * Trial participants who are pregnant or breastfeeding; * Evidence of a serious illness/condition or unstable clinical condition, or localized active infection/infectious disease; * Any major surgery performed within 30 days prior to the first dose of study treatment, or any planned surgery during the study; * Cancer or a history of cancer or lymphoproliferative disease within the past 5 years; * New York Heart Association (NYHA) Class III or IV congestive heart failure, or any recent episode of heart failure resulting in NYHA Class III/IV symptoms; or a history of clinically significant ventricular arrhythmia or arrhythmia requiring continuous antiarrhythmic drug therapy; * Uncontrolled hypertension at screening or randomization; * History of thrombotic disease within 24 weeks prior to screening; viii. History of acute coronary syndrome and/or any major cerebrovascular disease within 24 weeks prior to screening; * Current or recent (within 3 months prior to randomization) gastrointestinal disease that may affect absorption of study treatment, including gastrointestinal surgery; * Severe blood loss (\> 500 mL) or blood transfusion within 4 weeks prior to randomization; * Inability to take oral medication; * Inability to undergo venipuncture and/or tolerate venous access; * History of substance abuse with inability to abstain or presence of a psychiatric disorder; * Any other medical, psychiatric, and/or social reason as determined by medical judgment; * Prior and concomitant medications: If the trial participant has a history of biologic use, the exclusion criteria specified in the protocol will apply; * Infection-related: * Active tuberculosis identified by chest radiography within 6 months prior to screening; trial participants with a negative chest radiography within 3 months prior to screening are eligible if they meet the protocol requirements; * Hepatitis C, hepatitis B, or human immunodeficiency virus (HIV) infection; or syphilis infection requiring treatment; * Abnormal physical examination or laboratory findings; * Other: * History of any major drug allergy; known allergy to any excipient of the investigational product; * Inability to comply with the trial protocol; * History of substance abuse with inability to abstain or presence of a psychiatric disorder; * Participation in another clinical trial and use of another investigational drug (other than for psoriatic arthritis) within 4 weeks prior to the first dose, based on the date of discontinuation from the previous trial; * Planned or previous allogeneic bone marrow transplantation or solid organ transplantation; * Any condition that, in the investigator's judgment, poses a serious risk to the safety of the trial participant or affects the participant's ability to complete the study.
Study design
Enrollment target: 156 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-07-16
Estimated completion: 2027-11
Last updated: 2026-09-02
Interventions
Drug: TQH3906 CapsuleDrug: TQH3906 Placebo CapsuleDrug: Tofacitinib Citrate Tablet 5 mg
Primary outcomes
  • • American College of Rheumatology 20% Improvement Criteria (Day 1, 15, 29, 57, 85, 113, 141, 169)
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · industry
Contacts & investigators
ContactXiaofeng Zeng, Doctor · contact · xiaofeng.zeng@cstar.org.cn · 13501069845
All locations (44)
Bozhou People's HospitalRecruiting
Bozhou, Anhui, China
Peking Union Medical College HospitalRecruiting
Beijing, Beijing Municipality, China
Southwest Hospital, Third Military Medical University (Army Medical University)Recruiting
Chongqing, Chongqing Municipality, China
Dongguan People's HospitalRecruiting
Dongguan, Guangdong, China
The First Affiliated Hospital, Guangzhou University of Traditional Chinese MedicineRecruiting
Guangzhou, Guangdong, China
The Third Affiliated Hospital of Sun Yat-sen UniversityRecruiting
Guangzhou, Guangdong, China
Jiangmen Central HospitalRecruiting
Jiangmen, Guangdong, China
Shenzhen Second People's HospitalRecruiting
Shenzhen, Guangdong, China
The Second Affiliated Hospital of Guangxi Medical UniversityRecruiting
Nanning, Guangxi, China
The Affiliated Hospital of Guizhou Medical UniversityWithdrawn
Guiyang, Guizhou, China
Bao Ding NO.1 CentralRecruiting
Baoding, Hebei, China
Hebei Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western MedicineRecruiting
Cangzhou, Hebei, China
Kaifeng People's HospitalRecruiting
Kaifeng, Henan, China
Luoyang Orthopedic-Traumatological Hospital Of Henan Province(Henan Provincial Orthopedic Hospital)Recruiting
Luoyang, Henan, China
The First Affiliated Hospital of Henan University of science and TechnologyNot Yet Recruiting
Luoyang, Henan, China
Puyang Oilfield General HospitalRecruiting
Puyang, Henan, China
The First Affiliated Hospital of Henan University of CMWithdrawn
Zhengzhou, Henan, China
Xiangya Hospital of Central South UniversityRecruiting
Changsha, Hunan, China
The Central Hospital of ShaoyangWithdrawn
Shaoyang, Hunan, China
Zhuzhou Central HospitalRecruiting
Zhuzhou, Hunan, China
Jiangsu Peopince HospitalRecruiting
Nanjing, Jiangsu, China
Nanjing Drum Tower HospitalRecruiting
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Soochow UniversityRecruiting
Suzhou, Jiangsu, China
Yancheng No.1 People's HospitalRecruiting
Yancheng, Jiangsu, China
The First Affiliated Hospital of Nanchang UniversityRecruiting
Nanchang, Jiangxi, China
The Second Affiliated Hospital of Nanchang UniversityRecruiting
Nanchang, Jiangxi, China
Pingxiang People's HospitalNot Yet Recruiting
Pingxiang, Jiangxi, China
Jilin Provincial People's HospitalRecruiting
Changchun, Jilin, China
The First Hospital of Jilin UniversityRecruiting
Changchun, Jilin, China
The second hospital of dalian medical universityWithdrawn
Dalian, Liaoning, China
The First Hospital of China Medical UniversityRecruiting
Shenyang, Liaoning, China
Shandong Provincial HospitalRecruiting
Jinan, Shandong, China
Weifang People'S HospitalRecruiting
Weifang, Shandong, China
Shanghai Tenth People's HospitalRecruiting
Shanghai, Shanghai Municipality, China
Linfen Central HospitalRecruiting
Linfen, Shanxi, China
Deyang People's HospitalRecruiting
Deyang, Sichuan, China
Affiliated Hospital of Southwest Medical UniversityRecruiting
Luzhou, Sichuan, China
Hospital of North Sichuan Medical CollegeRecruiting
Nanchong, Sichuan, China
Tianjin Academy of Traditional Chinese Medicine Affiliated HospitalRecruiting
Tianjin, Tianjin Municipality, China
Tianjin Academy of Traditional Chinese Medicine Affiliated HospitalRecruiting
Tianjin, Tianjin Municipality, China
Xinjiang Uygur Autonomous Region People's HospitalWithdrawn
Ürümqi, Xinjiang, China
Sir Run Run Shaw Hospital, Zhejiang University School of MedicineRecruiting
Hangzhou, Zhejiang, China
The First Affiliated Hospital, Zhejiang University School of MedicineNot Yet Recruiting
Hangzhou, Zhejiang, China
Ningbo Medical Center Li HuiLi HospitalRecruiting
Ningbo, Zhejiang, China
A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis · TrialPath